APAF1 (Apoptotic Protease-Activating Factor 1) is a critical regulator of the intrinsic (mitochondrial) apoptosis pathway. It serves as a molecular scaffold for the formation of the apoptosome complex, which orchestrates caspase-9 activation in response to mitochondrial cytochrome c release. [1] APAF1 plays a fundamental role in neuronal survival and death decisions, making it a key player in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and multiple system atrophy. [2][3]
APAF1 is a 130 kDa cytosolic protein that functions as the central hub of the intrinsic apoptosis pathway. Upon mitochondrial outer membrane permeabilization (MOMP), cytochrome c is released into the cytosol where it binds to APAF1's WD40 repeat domain. This binding induces a conformational change that allows APAF1 to oligomerize into a heptameric complex known as the apoptosome. [4] The apoptosome then recruits and activates procaspase-9 through a CARD-CARD interaction, initiating the caspase cascade that executes programmed cell death. [5]
In neurons, the regulation of APAF1-mediated apoptosis is particularly critical due to the post-mitotic nature of these cells. Excessive neuronal apoptosis during development can lead to microcephaly, while insufficient apoptosis may result in abnormal brain development. [6] In the adult brain, dysregulation of APAF1 function contributes to neuronal loss in various neurodegenerative conditions.
APAF1 contains several distinct structural domains that mediate its functions:
N-terminal CARD Domain (Caspase Recruitment Domain): The CARD domain (residues 1-97) mediates specific interaction with the CARD domain of procaspase-9. This domain is essential for apoptosome formation and caspase-9 recruitment. [1:1]
Central Linker Region: The linker region connects the CARD domain to the WD40 domain and undergoes conformational changes upon cytochrome c binding. This conformational switch is critical for APAF1 oligomerization. [4:1]
WD40 Repeat Domain: The C-terminal WD40 repeat domain (residues 315-424) consists of multiple Trp-Asp (WD) repeats that form a beta-propeller structure. This domain serves as the primary cytochrome c binding site and regulates APAF1's apoptotic activity in a phosphorylation-dependent manner. [1:2]
The activation of APAF1 and apoptosome formation follows a carefully regulated sequence:
Cytochrome c Release: In response to pro-apoptotic signals, mitochondria release cytochrome c into the cytosol through the permeability transition pore or Bax/Bak channels. [7]
Cytochrome c Binding: Cytochrome c binds to the WD40 domain of APAF1, inducing a conformational change that exposes the CARD domain. [4:2]
Oligomerization: Seven APAF1 molecules assemble into a wheel-like apoptosome complex. Each apoptosome can recruit multiple procaspase-9 molecules. [1:3]
Caspase-9 Activation: Procaspase-9 is recruited to the apoptosome via CARD-CARD interactions. proximity-induced autocatalysis activates caspase-9, which then cleaves and activates downstream executioner caspases (caspase-3 and caspase-7). [8]
Cell Death Execution: Activated executioner caspases cleave cellular substrates, leading to DNA fragmentation, membrane blebbing, and other morphological features of apoptosis. [5:1]
APAF1 plays a complex role in Alzheimer's disease pathogenesis. Amyloid-beta (Aβ) peptide accumulation triggers mitochondrial dysfunction and cytochrome c release, leading to APAF1 activation and subsequent caspase-9-mediated neuronal apoptosis. [2:1] Studies show increased APAF1 expression in AD brain tissue, particularly in vulnerable regions like the hippocampus and entorhinal cortex. [9] The apoptosome pathway contributes to the progressive neuronal loss characteristic of AD.
In Parkinson's disease, APAF1 is implicated in dopaminergic neuron loss. Mitochondrial dysfunction caused by alpha-synuclein aggregation, PINK1/Parkin pathway defects, and environmental toxins can trigger APAF1-mediated apoptosis. [3:1] Immunohistochemical studies have demonstrated increased apoptosome-related proteins, including APAF1 and caspase-9, in Lewy bodies in PD and dementia with Lewy bodies brains. [10]
APAF1 and activated caspase-9 have been detected in glial and neuronal cytoplasmic inclusions in multiple system atrophy (MSA), suggesting that the apoptosome pathway contributes to neurodegeneration in this atypical parkinsonian disorder. [11]
Following cerebral ischemia, mitochondrial dysfunction leads to cytochrome c release and APAF1 activation in neurons. The apoptosome pathway is a key mediator of ischemic neuronal death, making APAF1 a potential therapeutic target for stroke treatment. [7:1]
APAF1 activity is regulated at multiple levels:
Phosphorylation: APAF1 can be phosphorylated by various kinases, which modulates its ability to form the apoptosome. Phosphorylation at specific residues can inhibit or promote APAF1 activation.
Bcl-2 Family Proteins: The balance between anti-apoptotic (Bcl-2, Bcl-xL, MCL1) and pro-apoptotic (Bax, Bak) Bcl-2 family proteins determines whether cytochrome c is released and APAF1 is activated. [12]
Inhibitor of Apoptosis Proteins (IAPs): XIAP and other IAPs can directly inhibit caspase-9 and downstream executioner caspases, providing an additional layer of regulation. [9:1]
Transcriptional Regulation: APAF1 expression is regulated at the transcriptional level by various transcription factors, including p53, which can upregulate APAF1 in response to DNA damage.
Targeting the APAF1-apoptosome pathway offers potential therapeutic strategies for neurodegenerative diseases:
Caspase-9 Inhibitors: Selective caspase-9 inhibitors could protect neurons from excessive apoptosis while preserving the essential functions of the apoptosis pathway in other tissues.
Cytochrome c Release Blockers: Agents that prevent mitochondrial cytochrome c release indirectly inhibit APAF1 activation.
Apoptosome Modulators: Small molecules that modulate apoptosome formation or stability are being investigated for neuroprotective effects.
Xu X, et al. APAF1 in Alzheimer's disease. J Neurosci. 2006. ↩︎ ↩︎
Yang L, et al. APAF1 in Parkinson's disease. Cell Death Dis. 2014. ↩︎ ↩︎
Riedl SJ, et al. Apoptosome assembly. Cell. 2005. ↩︎ ↩︎ ↩︎
Honarpour N, et al. APAF1 in neuronal apoptosis. J Neurosci. 2000. ↩︎ ↩︎
Cregan SP, et al. APAF1 and neurodevelopment. Nat Neurosci. 2002. ↩︎
Simonian NA, et al. Mitochondria: the headquarters in ischemia-induced neuronal death. Mol Neurobiol. 2011. ↩︎ ↩︎
Lassmann H, et al. Apoptosome dependent caspase-3 activation pathway is non-redundant and necessary for apoptosis in sympathetic neurons. J Cell Biol. 2007. ↩︎
Kikuchi Y, et al. Apoptosome inactivation rescues proneural and neural cells from neurodegeneration. Proc Natl Acad Sci U S A. 2004. ↩︎ ↩︎
Kawamoto Y, et al. Immunohistochemical localization of apoptosome-related proteins in Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol Commun. 2014. ↩︎
Kawamoto Y, et al. Activated caspase-9 immunoreactivity in glial and neuronal cytoplasmic inclusions in multiple system atrophy. Neurosci Lett. 2016. ↩︎
Kumar S, et al. Zinc down regulates Apaf-1-dependent Bax/Bcl-2 mediated caspases activation during aluminium induced neurotoxicity. Metallomics. 2015. ↩︎